Heritage Trust Co Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Heritage Trust Co bought a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,101 shares of the medical research company's stock, valued at approximately $2,633,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Blossom Wealth Management increased its holdings in Amgen by 3.5% during the 4th quarter. Blossom Wealth Management now owns 1,090 shares of the medical research company's stock worth $284,000 after acquiring an additional 37 shares during the period. Zullo Investment Group Inc. raised its position in shares of Amgen by 2.8% in the fourth quarter. Zullo Investment Group Inc. now owns 1,364 shares of the medical research company's stock worth $356,000 after buying an additional 37 shares in the last quarter. Trillium Asset Management LLC raised its position in shares of Amgen by 4.2% in the fourth quarter. Trillium Asset Management LLC now owns 911 shares of the medical research company's stock worth $237,000 after buying an additional 37 shares in the last quarter. Evermay Wealth Management LLC boosted its stake in Amgen by 1.5% during the fourth quarter. Evermay Wealth Management LLC now owns 2,650 shares of the medical research company's stock valued at $691,000 after buying an additional 38 shares during the period. Finally, Great Lakes Retirement Inc. grew its position in Amgen by 0.4% during the fourth quarter. Great Lakes Retirement Inc. now owns 10,220 shares of the medical research company's stock worth $2,664,000 after buying an additional 38 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Amgen Trading Up 0.5 %

NASDAQ AMGN traded up $1.38 on Tuesday, hitting $295.30. The company's stock had a trading volume of 2,592,052 shares, compared to its average volume of 2,777,829. The firm has a market cap of $158.77 billion, a P/E ratio of 39.11, a PEG ratio of 2.63 and a beta of 0.59. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company's 50-day simple moving average is $304.05 and its 200 day simple moving average is $294.91. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Research analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a dividend yield of 3.22%. Amgen's dividend payout ratio is presently 126.09%.

Insider Buying and Selling

In other Amgen news, EVP Jonathan P. Graham sold 25,045 shares of the firm's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the sale, the executive vice president now directly owns 28,987 shares in the company, valued at approximately $8,496,669.44. This trade represents a 46.35 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David M. Reese sold 8,711 shares of the company's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the completion of the transaction, the executive vice president now owns 62,147 shares in the company, valued at approximately $18,222,743.34. This represents a 12.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock valued at $20,644,335 over the last ninety days. Company insiders own 0.69% of the company's stock.

Analyst Ratings Changes

AMGN has been the subject of a number of research analyst reports. Bank of America lifted their price target on Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research report on Wednesday, March 5th. Morgan Stanley lifted their target price on shares of Amgen from $328.00 to $330.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 9th. Citigroup reissued a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Amgen in a report on Wednesday, February 5th. Finally, StockNews.com raised Amgen from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, April 9th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Amgen currently has an average rating of "Moderate Buy" and an average price target of $314.91.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.